Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- The Third Affiliated Hospital of Sun Yat-sen University
- Modality
- Small Molecules, Peptides, Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
PEG-Interferon Alfa + Tenofovir Disoproxil Fumarate is a combination antiviral regimen consisting of peginterferon alfa, a pegylated biologic immunomodulator, and tenofovir disoproxil fumarate (TDF), a small molecule nucleotide reverse transcriptase inhibitor. This regimen is primarily investigated for the treatment of chronic hepatitis B virus (HBV) infection and HBV-related liver fibrosis. Peginterferon alfa works by binding to the interferon alpha/beta receptor (IFNAR), stimulating the innate immune system and activating signaling pathways that inhibit viral replication and enhance the host immune response. Tenofovir disoproxil fumarate, a prodrug of tenofovir, acts by inhibiting HBV DNA polymerase/reverse transcriptase, leading to chain termination of the viral DNA. The combination is being evaluated for its potential to achieve HBsAg seroclearance (functional cure) and reverse liver fibrosis in patients who are already experienced with nucleos(t)ide analogue therapy.
- Other names
- pegylated interferon alpha + tenofovir disoproxil fumaratepeg-IFN-α + TDF
02
Targets
HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on peginterferon alfa + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa + tenofovir disoproxil fumarate.